CL · Intrinsic value
Is Colgate-Palmolive Company (CL) overvalued or undervalued?
Colgate-Palmolive Company (CL) trades at the delayed market price of $94.11 a share. That price already implies revenue growth of 6.4% a year for 5 years. TickerWorth's fair value is $85.39 a share (priced within our range of $52.80 – $121.84). We do not call it over- or undervalued from inside our range.
Model by Miraaj Patel · generated from SEC filings and market data · Updated Oct 19, 2026 · How these pages are made
Is CL fairly valued?
- Fair value
- $85.39
- Market price
- $94.11
- Downside to fair value
- 9.3%
- Verdict
- Priced within our range of $52.80 – $121.84
Reverse DCF: Today's price implies revenue growth of 6.4% a year for 5 years; our model assumes 4.2% a year on average over the same horizon.
What is CL's TickerWorth Score?
Middle of the pack — real strengths and real weaknesses
Compared with Consumer Defensive companies in US
Its strongest point: a profitable, high-quality business. Its weakest: looks expensive on the numbers.
- Value · 21 of 100
Cheaper than 21% of Consumer Defensive companies in US
- Price vs worth · 43 of 100
- Quality · 79 of 100
More profitable than 79% of Consumer Defensive companies in US
- Financial health · 50 of 100
Financially stronger than 50% of Consumer Defensive companies in US
- Growth · 54 of 100
Growing faster than 54% of Consumer Defensive companies in US
- Momentum · 81 of 100
Outperformed 81% of Consumer Defensive companies in US over the past year
Confidence: High confidence · Scored
Get the Undervalued Company of the Week.
CL DCF valuation, input by input
TickerWorth's fair value for Colgate-Palmolive Company (CL) is $85.39 a share, against the delayed market price of $94.11 (priced within our range of $52.80 – $121.84). We do not call it over- or undervalued from inside our range. It is a model estimate, and every input behind it is sourced below. This is an educational model, not a price target or a recommendation.
Read the full reasoning
One of the lenses behind that blended figure is a discounted-cash-flow model, which on its own values CL at about $82.64 per share. The rest of this page walks through that DCF — its assumptions, reverse-DCF and discount-rate sensitivity — because it is the auditable anchor of the blend.
The valuation discounts Colgate-Palmolive Company's projected free cash flows at a weighted-average cost of capital (WACC) of 6.9%, with a long-run terminal growth rate of 2.5%. About 82% of the enterprise value comes from the terminal value — the portion beyond the explicit forecast window — which is typical for a stable, cash-generative business and a reminder that small changes in the discount rate or terminal growth assumption swing the intrinsic value meaningfully.
Running the DCF in reverse — solving for the growth the current price already assumes — the market is implying roughly 6.4% annual revenue growth for CL. Our base case instead compounds to about 4.2% a year over the same forecast, so the market is pricing in materially faster growth than our base case. The reverse-DCF is a quick sanity check: it reframes 'is this stock cheap?' as 'do I believe the growth the price requires?' rather than arguing over a single point estimate of fair value.
Sensitivity matters more than any single number. Across a reasonable band of discount-rate assumptions, CL's modeled DCF value ranges from about $51.40 to $194.15 per share. If that range still sits below today's price, the market is optimistic relative to the model across the whole band; if it brackets the price, the stock is roughly fairly valued on our assumptions. Use the interactive slider to see exactly where your own cost-of-capital view lands.
How to read this page: the DCF fair value is what Colgate-Palmolive Company would be worth if its cash flows grow as modeled and are discounted at the stated WACC. The assumptions table shows every input and its source; the reverse-DCF shows what the market believes; the sensitivity band shows how fragile the answer is. None of this is investment advice — it is a transparent, auditable framework for forming your own view of CL's intrinsic value. Figures update as new filings and prices come in.
Every input behind CL's DCF
| Input | Value |
|---|---|
| Base-year revenueCOLGATE-PALMOLIVE COMPANY FY2025 10-K (accession 0000021665-26-000006): us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, FY2025 full year. | $20,382,000,000 |
| Base EBIT marginCOLGATE-PALMOLIVE COMPANY FY2025 10-K (accession 0000021665-26-000006): us-gaap:OperatingIncomeLoss 3,306,000,000 / revenue 20,382,000,000 = 16.22%, FY2025. | 16.2% |
| Forecast revenue growthESTIMATEAssumption — TickerWorth's 5-year explicit forecast | 4% → 4% → 4% → 4% → 4% |
| Risk-free rateLive feed — US 10-year Treasury yield (^TNX) | 5.2% |
| BetaLive feed — yfinance, 5-year monthly beta vs the S&P 500 (clamped to 0.4–2.5) | 0.40 |
| Terminal growthESTIMATEAssumption — TickerWorth house default 2.5%, held below WACC | 2.5% |
| Diluted sharesCOLGATE-PALMOLIVE COMPANY FY2025 10-K (accession 0000021665-26-000006): WeightedAverageNumberOfDilutedSharesOutstanding = 811,100,000 shares, FY2025. | 811M |
| Market priceDelayed quote · as of 2026-10-19 13:53 UTC | $94.11 |
Change CL's assumptions
The discount-rate dial and the editable model
ProChange growth, margin and WACC yourself — Pro (7-day free trial, card required).
What does Colgate-Palmolive Company do?
What does it do?
Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. It operates in the Household & Personal Products industry (Consumer Defensive sector), headquartered in United States. The company employs roughly 33,600 people.
How does it make money?
The business turns $21.0B in annual revenue into profit. Out of every $100 of sales, about $21 is left as operating profit (operating margin of 21.0%), after a 60% gross margin on the products/services it sells. After all costs, taxes and interest, 9.7% of revenue becomes bottom-line net profit.
Is it financially healthy?
Financially it looks stretched: carries heavy debt (13.9× equity), can just cover its short-term bills (1.0× current ratio), and is currently profitable.
CL insider trading
We have no recent SEC Form 4 insider filings on file for Colgate-Palmolive Company. Form 4 covers US-listed companies only.
Common questions
What is CL's intrinsic value?
TickerWorth's blended fair value for Colgate-Palmolive Company (CL) is $85.39 per share, versus a market price of $94.11 (priced within our range of $52.80 – $121.84).
Is CL overvalued or undervalued?
Priced within our range of $52.80 – $121.84 at $94.11. We don't call CL overvalued or undervalued from a range. This is an educational estimate, not advice.
What discount rate is used for CL?
A WACC of 6.9% and a terminal growth rate of 2.5%.
Is Colgate-Palmolive stock undervalued?
TickerWorth's fair value for Colgate-Palmolive Company (CL) is $85.39 against a market price of $94.11. Our read: Priced within our range of $52.80 – $121.84. This is a model estimate, not investment advice.
Colgate-Palmolive (CL) DCF valuation and fair value
Our fair value for Colgate-Palmolive Company (CL) is $85.39, built on a 6.9% discount rate (WACC) and 2.5% terminal growth. It blends our discounted-cash-flow model with other valuation lenses. Every assumption is listed on this page with its source.
What growth is priced into Colgate-Palmolive stock?
Today's price implies revenue growth of 6.4% a year for 5 years; our model assumes 4.2% a year on average over the same horizon. This is a reverse DCF: it holds our cash-flow model's other inputs and solves for the revenue growth that makes the model equal today's price of $94.11. A model estimate, not investment advice.
Colgate-Palmolive (CL) insider trading
We have no recent SEC Form 4 insider filings on file for Colgate-Palmolive Company (CL). Form 4 covers US-listed companies only.
People who read CL also read
Not investment advice. TickerWorth Score is a model output.
Educational tool. Every output reflects the assumptions shown — not a prediction and not investment advice. TickerWorth is not a licensed investment adviser, and these figures are estimates from public filings and market data that can be wrong.